New trial
A Pilot Study Comparing Neoadjuvant and Adjuvant GVAX vs a Mutated KRAS Peptide Vaccine Given With Anti-PD-1 and Anti-CD137 for the Treatment of Surgically Resectable Pancreatic Adenocarcinoma
- Trial ID
- NCT06782932 on ClinicalTrials.gov
- Cancer type
- Pancreatic Ductal Adenocarcinoma (PDAC)
- Published in
- New in Oncology - May 21, 2025
Johns Hopkins is investigating the optimal dosing and safety of AGEN2373 combined with balstilimab alongside either GVAX or a mutated KRAS peptide vaccine, aimed at enhancing neoadjuvant and adjuvant treatment efficacy in newly diagnosed resectable pancreatic adenocarcinoma.
More in pancreatic cancer
-
Trial result · Oct 15, 2026 · NCT04543071
Motixafortide (CXCR4 inhibitor) + cemiplimab (PD-1) + gem/nab-paclitaxel posts 55% confirmed ORR in 1L metastatic PDAC -
Trial result · Oct 15, 2026 · NCT06850623
ACT (PS101 + focused ultrasound) plus mFOLFIRINOX shows early responses and a resection conversion signal in locally advanced/borderline PDAC -
Trial result · Oct 15, 2026 · NCT07562152
Atebimetinib (deep cyclic MEK inhibitor) + mGnP links weight preservation to longer OS in 1L pancreatic cancer -
New trial · Oct 15, 2026 · NCT07619521
Phase 1/2 selumetinib plus trastuzumab deruxtecan targets KRAS-mutant, HER2-expressing pancreatic cancer -
New trial · Oct 15, 2026 · NCT07824960
Phase 1b/2 avutometinib plus defactinib adds RAF/MEK and FAK inhibition to mFOLFIRINOX in pancreatic cancer